COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance

Medical device company CooperCompanies (NASDAQ:COO) missed Wall Street’s revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion. The company’s full-year revenue guidance of $4.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.7% above analysts’ consensus estimates.